No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NSPR240719C2500
- 0.15
- -0.05-25.00%
15min DelayClose Jul 1 15:58 ET
0.15High0.15Low
0.15Open0.20Pre Close3 Volume3 Open Interest2.50Strike Price45.00Turnover80.86%IV8.61%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type0.4870Delta0.9150Gamma16.27Leverage Ratio-0.0051Theta0.0005Rho7.92Eff Leverage0.0021Vega
Intraday
- 5D
- Daily
News
InspireMD Brings in $17.9M to Support Stent Trial
InspireMD Secures Funds to Expand Healthcare Innovations
Express News | InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million
Express News | InspireMD: Files Prospectus Supplement to Offer, Sell Common Stock of up to $17 Mln From Time to Time Under Equity Distribution Deal With Piper Sandler
InspireMD's CGuard Stent Shows Promise in C-GUARDIANS Trial
Express News | InspireMD Presents One-Year Follow-Up Results From C-GUARDIANS US IDE Trial Of CGuard At LINC 2024 On May 28 At 8:53 A.m. EDT
Comments
$InspireMD(NSPR.US$ InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million
$InspireMD(NSPR.US$ InspireMD Inc -U.S. Commercial Launch of Cguard™ Prime Carotid Stent System Anticipated in H1 2025, IF Approved
$InspireMD(NSPR.US$ INSPIREMD INC -STUDY RESULTS TO SUPPORT A PREMARKET APPROVAL (PMA) APPLICATION TO FDA IN H2 2024
Reuters05/28/2024 08:53
Reuters05/28/2024 08:53
$InspireMD(NSPR.US$ InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.15) by 40 percent. This is a 60.38 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $1.511 billion which beat the analyst consensus estimate of $1.384 million by 109.08K percent. This is a 121.85K percent increase over sales of $1.239 million the same period...
$InspireMD(NSPR.US$ InspireMD Announces Abstract Of One-year Follow-up Results From C-GUARDIANS U.S. Investigational Device Exemption Clinical Trial Accepted For Presentation At LINC 2024
Benzinga· 1 min ago
Benzinga· 1 min ago
Read more